Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 9/2019

23.08.2019 | Original Article

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer

verfasst von: Mohamed Badr, Korinna Jöhrens, Michael Allgäuer, Melanie Boxberg, Wilko Weichert, Ingeborg Tinhofer, Carsten Denkert, Peter Schirmacher, Albrecht Stenzinger, Jan Budczies

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Immunotherapy is effective in head and neck squamous cell carcinoma (HNSCC), but only a minority of patients responds to immune checkpoint blockade (ICB). To contribute to a better understanding of the underlying immune biology, we combined histomorphological evaluation and molecular analysis of the HNSCC immune microenvironment in the TCGA cohort. Analyzing digital HE-stained slides, a method for classification of tumor infiltrating lymphocytes (TILs) in the intra-epithelial compartment (ieTILs, present vs. absent) and the stromal compartment (strTILs, high vs. low) was established. We also analyzed the abundance of eight immune cell populations (estimated from RNAseq data) and PD-L1 mRNA expression. Status of ieTILs and status of strTILs were concordant for 61%, but discordant for 39% of tumors. In univariate survival analysis, ieTILs were a positive prognostic marker for DFS in the study cohort (HR = 0.66, p = 0.015) and in the HPV− subcohort (HR = 0.68, p = 0.04), but not in the HPV + subcohort. T cells were a positive prognostic marker for DFS in the study cohort (HR = 0.80, p = 0.03) and in the HPV + subcohort (HR = 0.20, p = 0.001), but not in the HPV− subcohort. In univariate survival analysis, PD-L1 mRNA expression was neither associated with DFS nor with OS. However, in bivariate and multivariate analyses including both PD-L1 mRNA levels and T cells, PD-L1 was a negative prognostic marker of DFS and OS, while T cells remained a positive prognostic marker. In conclusion, ieTILs and strTILs were non-redundant biomarkers in HNSCC and should be evaluated separately. The identified prognostic markers should be evaluated for predictivity in ICB-treated patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
15.
Zurück zum Zitat Ferris RL, Blumenschein J, George Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML (2018) Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2018.04.008 CrossRefPubMedPubMedCentral Ferris RL, Blumenschein J, George Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML (2018) Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. https://​doi.​org/​10.​1016/​j.​oraloncology.​2018.​04.​008 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. https://doi.org/10.1056/nejmoa1602252 CrossRefPubMedPubMedCentral Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. https://​doi.​org/​10.​1056/​nejmoa1602252 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. https://doi.org/10.1016/s1470-2045(16)30066-3 CrossRefPubMed Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. https://​doi.​org/​10.​1016/​s1470-2045(16)30066-3 CrossRefPubMed
19.
Zurück zum Zitat Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck Iris, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin C-C, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R (2018) Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. https://doi.org/10.1038/s41416-018-0131-9 CrossRefPubMedPubMedCentral Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck Iris, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin C-C, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R (2018) Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. https://​doi.​org/​10.​1038/​s41416-018-0131-9 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R (2019) Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥ 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. https://doi.org/10.1016/j.ejca.2018.11.015 CrossRefPubMed Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R (2019) Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥ 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. https://​doi.​org/​10.​1016/​j.​ejca.​2018.​11.​015 CrossRefPubMed
23.
Zurück zum Zitat Cohen EEW, Cohen E, Soulières D, Le Tourneau C, Dinis J, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness BA, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington K, Harrington KJ, Acosta-Rivera M, Adkins DR, Aghmesheh M, Airoldi M, Aleknavicius E, Al-Farhat Y, Algazi AP, Almokadem S, Alyasova A, Bauman JR, Benasso M, Berrocal A, Bray V, Caponigro F, Castro A, Cescon TP, Chan K, Chaudhry A, Chauffert B, Csoszi T, De Boer JP, Delord J, Dietz A, Dupuis C, Digue L, Erfan J, Escobar Alvarez Y, Evans M, Fidler MJ, Forster MD, Friesland S, Ganti AK, Geoffrois L, Grant C, Gruenwald V, Hoffmann T, Horvai G, Inciura A, Jang R, Jankowska P, Jimeno A, Joseph M, Juarez Ramiro A, Karaszewska B, Kawecki A, Keilholz U, Keller U, Kim S, Kocsis J, Kotecki N, Kozloff MF, Lambea J, Landherr L, Lantsukhay Y, Lazarev SA, Lee LW, Lifirenko ID, Martincic D, Matorin OV, McGrath M, Misiukiewicz K, Morris JC, Mufazalov FF, Niu J, Pamoorthy Srinivasan D, Perez Segura P, Rauch D, Ribeiro ML, Rodriguez C, Rolland F, Russo A, Ruzsa A, Sanches F, Shin S, Shtiveland M, Soulieres D, Specenier P, Szekanecz E, Szota J, van Herpen CML, Velez-Cortes HA (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. https://doi.org/10.1016/s0140-6736(18)31999-8 CrossRefPubMedPubMedCentral Cohen EEW, Cohen E, Soulières D, Le Tourneau C, Dinis J, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness BA, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington K, Harrington KJ, Acosta-Rivera M, Adkins DR, Aghmesheh M, Airoldi M, Aleknavicius E, Al-Farhat Y, Algazi AP, Almokadem S, Alyasova A, Bauman JR, Benasso M, Berrocal A, Bray V, Caponigro F, Castro A, Cescon TP, Chan K, Chaudhry A, Chauffert B, Csoszi T, De Boer JP, Delord J, Dietz A, Dupuis C, Digue L, Erfan J, Escobar Alvarez Y, Evans M, Fidler MJ, Forster MD, Friesland S, Ganti AK, Geoffrois L, Grant C, Gruenwald V, Hoffmann T, Horvai G, Inciura A, Jang R, Jankowska P, Jimeno A, Joseph M, Juarez Ramiro A, Karaszewska B, Kawecki A, Keilholz U, Keller U, Kim S, Kocsis J, Kotecki N, Kozloff MF, Lambea J, Landherr L, Lantsukhay Y, Lazarev SA, Lee LW, Lifirenko ID, Martincic D, Matorin OV, McGrath M, Misiukiewicz K, Morris JC, Mufazalov FF, Niu J, Pamoorthy Srinivasan D, Perez Segura P, Rauch D, Ribeiro ML, Rodriguez C, Rolland F, Russo A, Ruzsa A, Sanches F, Shin S, Shtiveland M, Soulieres D, Specenier P, Szekanecz E, Szota J, van Herpen CML, Velez-Cortes HA (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. https://​doi.​org/​10.​1016/​s0140-6736(18)31999-8 CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Nordfors C, Grün N, Tertipis N, Ährlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund L, Munck-Wikland E, Näsman A, Ramqvist T, Dalianis T (2013) CD8 + and CD4 + tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer. https://doi.org/10.1016/j.ejca.2013.03.019 CrossRefPubMed Nordfors C, Grün N, Tertipis N, Ährlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund L, Munck-Wikland E, Näsman A, Ramqvist T, Dalianis T (2013) CD8 + and CD4 + tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. Eur J Cancer. https://​doi.​org/​10.​1016/​j.​ejca.​2013.​03.​019 CrossRefPubMed
38.
Zurück zum Zitat Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A (2016) Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-15-1543 CrossRefPubMed Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A (2016) Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. https://​doi.​org/​10.​1158/​1078-0432.​ccr-15-1543 CrossRefPubMed
40.
Zurück zum Zitat Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. https://doi.org/10.1200/jco.2009.23.7370 CrossRefPubMed Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. https://​doi.​org/​10.​1200/​jco.​2009.​23.​7370 CrossRefPubMed
41.
Zurück zum Zitat Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer J, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. https://doi.org/10.1016/s1470-2045(17)30904-x CrossRefPubMed Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer J, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. https://​doi.​org/​10.​1016/​s1470-2045(17)30904-x CrossRefPubMed
Metadaten
Titel
Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer
verfasst von
Mohamed Badr
Korinna Jöhrens
Michael Allgäuer
Melanie Boxberg
Wilko Weichert
Ingeborg Tinhofer
Carsten Denkert
Peter Schirmacher
Albrecht Stenzinger
Jan Budczies
Publikationsdatum
23.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 9/2019
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02378-w

Weitere Artikel der Ausgabe 9/2019

Cancer Immunology, Immunotherapy 9/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.